Latest News and Press Releases

INDIANAPOLIS, June 28, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to advancing precision radioligand therapy for the treatment of cancer,...

INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer...

INDIANAPOLIS, April 28, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer...

TORONTO, March 23, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...

POINT Biopharma has entered into a definitive merger agreement with Research Alliance Corp. I (Nasdaq: RACA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker...

TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...

Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated...

POINT Acquires exclusive rights to breakthrough pan-cancer treatment TORONTO and BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT) today announced that it has entered into a...

TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...

TORONTO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, is...